Chris Forte’s Thoughts to Start the Day – XAIR, TGLS, INMB

Posted on April 26, 2022 by Scott Shuda

April 26: A few thoughts to start the day. . . J.P. Morgan’s strategist Marko Kolanovic said yesterday, “We see risks skewed toward a near-term equity rally given weak investor sentiment, low positioning, systematic strategy buying, seasonality, and oversold conditions.” This is one of those “gut check” times for microcap investors as the landscape is littered with the carcasses of small companies with bright futures and they are there for the taking at bargain prices. All it takes is Conviction with a capital “C”.


Yesterday Breakout Investors got a lift from four companies. Beyond Air (XAIR) checked in with two news releases. XAIR makes a healthcare device called Lungfit Pro that produces Nitric Oxide (NO) from ambient air which could address many massive markets in respiratory care. The company announced data on a study of Covid infected patients that showed the duration of oxygen treatment was significantly shorter for patients who received NO. XAIR also released news stating “Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022.” XAIR rose 12% on the day.


Another big mover was Technoglass (TGLS) which announced the listing of its ordinary shares to NYSE from Nasdaq. “ Shares closed up 11%. . . WELL Health Technologies Corp. (WLYYF), under-appreciated and expertly covered by Ashleigh Day announced “Business Update Reflecting Strong Growth and Enhanced Revenue Outlook for Q1-2022.” WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools. “We are pleased to report that WELL is on the cusp of delivering its best ever quarter of revenue performance in Q1 which is generally a quarter that is adversely affected by seasonality. We look forward to reporting our Q1 results and remain very positive on our business.” .


INmune Bio (INMB) also covered in Ashleigh’s room closed up 16%. Keep an eye on the clinical-stage immunology company focused on developing treatments that harness the immune system to fight disease including Alzheimer’s. . . “That’s right, people. Twitter said it would never sell to Elon Musk, and then he produced the cash and they’re like, ‘All right, we’ll sell.’ Yeah, I guess they found that edit button after all.” — TREVOR NOAH. . . Good luck to all.

 Join us on the Breakout Investor Platform (BIP) to discuss XAIR, TGLS, INMB and other great little companies where our community shares research and analysis.  We seek to be Ahead of the Curve in identifying and owning great companies with catalysts that could make them the next Breakout Investment. Membership and most of the content on BIP is free.

Download the Breakout Investors app to join the conversation.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x